EUVIMEDEUVIMED entdecken
Open Access

Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data

Levente Lippenszky iD, Kathleen F Mittendorf iD, Zoltán Kiss, Michele L LeNoue-Newton iD, Pablo Napan-Molina, Protiva Rahman iD, Cheng Ye, Balázs Laczi, Eszter Csernai, Neha M Jain iD, Marilyn E Holt iD, Christina N Maxwell und 10 weitere

JCO Clinical Cancer Informatics · 2024

DOI: 10.1200/cci.23.00207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von Levente Lippenszky und 21 weiteren Autor:innen. Beteiligte Einrichtung: Science and Technology Organization-Artificial Intelligence & Machine Learning, GE HealthCare, Budapest, Hungary/San Ramon, CA. Hauptthemen laut MEDLINE: Colitis, Hepatitis, Pneumonia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Although immune checkpoint inhibitors (ICIs) have improved outcomes in certain patients with cancer, they can also cause life-threatening immunotoxicities. Predicting immunotoxicity risks alongside response could provide a personalized risk-benefit profile, inform therapeutic decision making, and improve clinical trial cohort selection. We aimed to build a machine learning (ML) framework using routine electronic health record (EHR) data to predict hepatitis, colitis, pneumonitis, and 1-year overall survival. METHODS Real-world EHR data of more than 2,200 patients treated with ICI through December 31, 2018, were used to develop predictive models. Using a prediction time point of ICI initiation, a 1-year prediction time window was applied to create binary labels for the four outcomes for each patient. Feature engineering involved aggregating laboratory measurements over appropriate time windows (60-365 days). Patients were randomly partitioned into training (80%) and test (20%) sets. Random forest classifiers were developed using a rigorous model development framework. RESULTS The patient cohort had a median age of 63 years and was 61.8% male. Patients predominantly had melanoma (37.8%), lung cancer (27.3%), or genitourinary cancer (16.4%). They were treated with PD-1 (60.4%), PD-L1 (9.0%), and CTLA-4 (19.7%) ICIs. Our models demonstrate reasonably strong performance, with AUCs of 0.739, 0.729, 0.755, and 0.752 for the pneumonitis, hepatitis, colitis, and 1-year overall survival models, respectively. Each model relies on an outcome-specific feature set, though some features are shared among models. CONCLUSION To our knowledge, this is the first ML solution that assesses individual ICI risk-benefit profiles based predominantly on routine structured EHR data. As such, use of our ML solution will not require additional data collection or documentation in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ColitisHepatitisPneumoniaHumansMaleMiddle AgedFemaleImmune Checkpoint InhibitorsAmbulatory Care Facilities

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Science and Technology Organization-Artificial Intelligence & Machine Learning, GE HealthCare, Budapest, Hungary/San Ramon, CA.
  • Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.
  • Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN.
  • Health Outcomes and Biomedical Informatics, University of Florida, Tallahassee, FL.
  • OneOncology, Nashville, TN.
  • Sarah Cannon Research Institute, Nashville, TN.

ORCID-Profile: Levente Lippenszky, Kathleen F Mittendorf, Michele L LeNoue-Newton, Protiva Rahman, Neha M Jain, Marilyn E Holt, Madeleine Ball, Margaret B Mitchell, Douglas B Johnson, David S Smith, Ben H Park, Christine M Micheel, Daniel Fabbri, Travis J Osterman

Förderung

  • NCATS NIH HHS

Zitieren

APA

Lippenszky, L., Mittendorf, K. F., Kiss, Z., LeNoue-Newton, M. L., Napan-Molina, P., Rahman, P., Ye, C., Laczi, B., Csernai, E., Jain, N. M., Holt, M. E., Maxwell, C. N., Ball, M., Ma, Y., Mitchell, M. B., Johnson, D. B., Smith, D. S., Park, B. H., Micheel, C. M., …, & Osterman, T. J. (2024). Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.23.00207

Vancouver

Lippenszky L, Mittendorf KF, Kiss Z, LeNoue-Newton ML, Napan-Molina P, Rahman P, et al. Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.23.00207

BibTeX
@article{Lippenszky2024,
  author = {Lippenszky, Levente and Mittendorf, Kathleen F and Kiss, Zoltán and LeNoue-Newton, Michele L and Napan-Molina, Pablo and Rahman, Protiva and Ye, Cheng and Laczi, Balázs and Csernai, Eszter and Jain, Neha M and Holt, Marilyn E and Maxwell, Christina N and Ball, Madeleine and Ma, Yufang and Mitchell, Margaret B and Johnson, Douglas B and Smith, David S and Park, Ben H and Micheel, Christine M and Fabbri, Daniel and Wolber, Jan and Osterman, Travis J},
  title = {Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data},
  journal = {JCO Clinical Cancer Informatics},
  year = {2024},
  doi = {10.1200/cci.23.00207}
}
Kostenlos starten →